Geoffrey Burgess, MD

Dr. Burgess is currently Chief Medical Officer at Glutalor Medical. Dr. Burgess just retired after 40 years practice as a family medicine specialist with focus on diabetes in west Philadelphia area. Dr. Burgess graduated from Pennsylvania State University College of Medicine in 1975. Dr. Burgess founded Gateway Medical Associates in 1986 and worked as Medical Director at Tandigm Health from 2014 to 2017.

Michael A Friedman, MD

Dr. Friedman is an experienced healthcare leader with a distinguished career in oncology research, regulatory strategy, and public healthcare policy.  He served as President and CEO of City of Hope, a leading cancer research, treatment and education institution, as well as director of the organization’s Comprehensive Cancer Center.  Before that, Dr. Friedman was SVP of R&D, medical and public policy for Pharmacia Corp.  Dr. Friedman previously served as deputy commissioner for the U.S. FDA, later serving as acting commissioner.  Dr. Friedman holds a MD degree from the University of Texas and received his bachelor’s degree from Tulane University.

Dr. Friedman currently serves on the board of Mannkind, Cytovia, Sermonix and as a trustee of Tulane University and on the California Stem Cell Oversight Board.  He has served as a nonexecutive director on the boards of the Celgene, Smith and Nephew, and Intuitive Surgical.

Gerard Marriott, PhD, Professor

Prof. Marriott received a BSc (Hons) in Biochemistry from Birmingham University in the UK in 1980, and a Ph.D. from the University of Illinois in 1987. He was awarded prestigious fellowships from the Alexander von Humboldt Stiftung. After serving as a C3-professor at the Max Planck Institute for Biochemistry in Martinsried, he was recruited by the University of Wisconsin-Madison in 1999 to lead a new biophotonics initiative. In 2009 he moved to the Bioengineering department at UC-Berkeley where he conducts research on the design and development of novel biosensors and technology platforms for multi-scale in vitro and in vivo imaging and tumor-targeted drug delivery.  Prof. Marriott is also a co-Director of the Center for Precision Medicine and Healthcare at the Tsinghua-Berkeley Shenzhen Institute, where he is developing innovative biosensors for wearable devices to monitor glucose, cancer biomarkers and circulating tumor cells.